Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.
van Kesteren C, Twelves C, Bowman A, Hoekman K, López-Lázaro L, Jimeno J, Guzman C, Mathôt RA, Simpson A, Vermorken JB, Smyth J, Schellens JH, Hillebrand MJ, Rosing H, Beijnen JH.
van Kesteren C, et al. Among authors: schellens jh.
Anticancer Drugs. 2002 Apr;13(4):381-93. doi: 10.1097/00001813-200204000-00007.
Anticancer Drugs. 2002.
PMID: 11984084
Clinical Trial.